Trial Profile
A Phase II Open-Label Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer and Good Performance Status
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs Devimistat (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 26 Jan 2024 Planned End Date changed from 1 Oct 2024 to 23 Sep 2024.
- 26 Jan 2024 Planned primary completion date changed from 1 Oct 2023 to 23 Sep 2024.
- 12 Jul 2023 Planned End Date changed from 1 Apr 2024 to 1 Oct 2024.